Mapping the brain-spinal cord interaction towards understanding and treatment of movement disorders
The Move2Treat project, funded by EIC Pathfinder Open, is at the forefront of groundbreaking research aimed at developing revolutionary technologies. This initiative supports the development of minimally invasive, soft multifunctional neural devices leading to improved mapping of brain and spinal cord neural activity. With a competitive success rate of just 6-7%, Move2Treat exemplifies a high-risk, high-gain endeavor, dedicated to realizing technological advancements that will significantly impact Europe and beyond.
Recent News
-
OPTOGEN 2025 – Where Photonics Meets Neuroscience
From 6–8 May, the Move2Treat team proudly participated in #OPTOGEN2025, the 10th edition of this premier conference bridging photonics and […]
-
Move2Treat participation in WSOF 2025 in Prague!
🌐 Celebrating Innovation at WSOF 2025 in Prague! 🌐 We’re thrilled to share that our partners from Cyprus University of […]
-
Move2Treat project meeting – M10
☀️ Two inspiring days under the Mediterranean sun! Yesterday and today, we had the pleasure of coming together in Limassol, […]
-
Illuminating the Nervous System with Light-Sheet Microscopy
Illuminating the Nervous System with Light-Sheet Microscopy! ✨🔬 Earlier this month at Blaze User Day, Dr. Grace Houser from University of […]
-
Move2Treat at OPTOGEN 2025
Move2Treat at OPTOGEN 2025 – Bridging Photonics and Neuroscience We are excited to share that OPTOGEN 2025, the 10th edition […]
-
Innovative Light Delivery for Neurological Research: A New Frontier
Move2Treat recent advancements in neuroscience research, published in Optics Letters, are being propelled by the development of tapered polymer optical […]
This project has received funding from the European Union’s Horizon EIC Pathfinder programme under grant agreement No. 101130161. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.